Endo Health Solutions | Endo International | off-label or unapproved promotion of medical products | 2021 | NY-AG | $50,000,000 |
Allergan Finance LLC | AbbVie | off-label or unapproved promotion of medical products | 2021 | NY-AG | $200,000,000 |
Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. | Endo International | off-label or unapproved promotion of medical products | 2022 | FL-AG | $65,000,000 |
Teva Pharmaceutical Industries Ltd. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | TX-AG | $225,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | FL-AG | $278,826,499 |
Allergan Ltd. et al. | AbbVie | off-label or unapproved promotion of medical products | 2022 | FL-AG | $134,200,000 |
Endo Health Solutions and Endo Pharmaceuticals | Endo International | off-label or unapproved promotion of medical products | 2022 | FL-AG | $65,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | RI-AG | $21,000,000 |
Allergan Ltd. | AbbVie | off-label or unapproved promotion of medical products | 2022 | RI-AG | $7,500,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | WV-AG | $83,000,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | WV-AG | $78,000,000 |
Janssen Pharmaceuticals | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | WV-AG | $99,000,000 |
Endo Pharmaceuticals | Endo International | off-label or unapproved promotion of medical products | 2022 | CA-SFCA | $10,000,000 |
Endo International plc | Endo International | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $450,000,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $2,370,000,000 |
Teva Pharmaceuticals | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $4,250,000,000 |
Janssen Pharmaceuticals/Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | NH-AG | $40,500,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | CA-SFCA | $27,000,000 |
Teva Parmaceuticals | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | CA-SFCA | $27,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | NH-AG | $40,500,000 |
Teva Pharmaceuticals, Ltd. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | NY-AG | $313,343,793 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $8,200,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $4,800,000 |
Teva Pharmaceuticals, Inc. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2023 | KY-AG | $71,477,474 |
Allergan PLC | AbbVie | off-label or unapproved promotion of medical products | 2023 | KY-AG | $48,666,145 |
Hikma Pharmaceuticals | Hikma Pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $150,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2024 | WA-AG | $149,500,000 |
Teva | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2024 | MD-AG | $70,281,867 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2024 | MD-AG | $38,166,450 |
Actavis Kadian, LLC | AbbVie | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $116,703 |
Intermune, Inc. | Roche | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $5,641 |
Intermune, Inc. | Roche | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $16,215 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2015 | CMS | $5,909 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2015 | CMS | $9,440 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2016 | CMS | $10,788 |
Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2016 | CMS | $12,367 |
Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2019 | CMS | $12,968 |
Wockhardt USA | Wockhardt Limited | Medicare Coverage Gap Discount Program violation | 2020 | CMS | $111,824 |
Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2023 | CMS | $31,959 |
Glenmark Pharmaceuticals, Inc. | Glenmark Pharmaceuticals | HHS civil monetary penalties | 2015 | HHSOIG | $2,887,300 |
Sandoz, Inc. | Sandoz Group | HHS civil monetary penalties | 2015 | HHSOIG | $12,640,000 |
Sandoz, Inc. | Sandoz Group | HHS civil monetary penalties | 2011 | HHSOIG | $230,000 |
Advanced Neuromodulation Systems, Inc. | Abbott Laboratories | HHS civil monetary penalties | 2007 | HHSOIG | $2,950,000 |
Mallinckrodt LLC | Mallinckrodt | Controlled Substances Act violation | 2017 | DEA | $35,000,000 |
Johnson & Johnson | Johnson & Johnson | Controlled Substances Act violation | 2008 | USAO | $511,000 |
Anda | Teva Pharmaceutical Industries | Controlled Substances Act violation | 2016 | WV-AG | $1,800,000 |
Purdue Frederick Company, Inc. and Purdue Pharma, L.P. | Purdue Pharma | Controlled Substances Act violation | 2007 | NV-AG | $1,047,787 |
Purdue Pharma | Purdue Pharma | Controlled Substances Act violation | 2019 | OK-AG | $270,000,000 |
Purdue Pharma, L.P. | Purdue Pharma | Controlled Substances Act violation | 2015 | NY-AG | $75,000 |
Teva Pharmaceuticals | Teva Pharmaceutical Industries | Controlled Substances Act violation | 2019 | OK-AG | $85,000,000 |
Mallinckrodt | Mallinckrodt | Controlled Substances Act violation | 2020 | MULTI-AG | $1,600,000,000 |
Endo Pharmaceuticals | Endo International | Controlled Substances Act violation | 2020 | OK-AG | $8,750,000 |